MedPath
HSA Approval

Candesartan Sandoz Tablet 8mg

SIN14302P

Candesartan Sandoz Tablet 8mg

Candesartan Sandoz Tablet 8mg

January 29, 2013

NOVARTIS (SINGAPORE) PTE LTD

SANDOZ SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD
Licence HolderSANDOZ SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C09CA06

candesartan

Manufacturer Information

SANDOZ SINGAPORE PTE. LTD.

Lek Pharmaceuticals d.d.

Lek Pharmaceuticals d.d (Lendava) (Primary Packager and Secondary Packager)

Active Ingredients

Candesartan 5.8mg eqv Candesartan Cilexetil

8mg

Candesartan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Candesartan Sandoz Tablet 8mg - HSA Approval | MedPath